Cargando…
A Systematic Review of the Cost-Effectiveness of Biologics for the Treatment of Inflammatory Bowel Diseases
BACKGROUND: Biologics are used for the treatment of inflammatory bowel diseases, Crohn´s disease and ulcerative colitis refractory to conventional treatment. In order to allocate healthcare spending efficiently, costly biologics for inflammatory bowel diseases are an important target for cost-effect...
Autores principales: | Huoponen, Saara, Blom, Marja |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4682717/ https://www.ncbi.nlm.nih.gov/pubmed/26675292 http://dx.doi.org/10.1371/journal.pone.0145087 |
Ejemplares similares
-
The Cost-Effectiveness of Biologics for the Treatment of Rheumatoid Arthritis: A Systematic Review
por: Joensuu, Jaana T., et al.
Publicado: (2015) -
Health-related quality of life and costs of switching originator infliximab to biosimilar one in treatment of inflammatory bowel disease
por: Huoponen, Saara, et al.
Publicado: (2020) -
Cost-effectiveness of abatacept, tocilizumab and TNF-inhibitors compared with rituximab as second-line biologic drug in rheumatoid arthritis
por: Huoponen, Saara, et al.
Publicado: (2019) -
Healthcare utilization, costs, and productivity losses in treatment-resistant depression in Finland – a matched cohort study
por: Taipale, Heidi, et al.
Publicado: (2022) -
A systematic review of cost-effectiveness studies comparing conventional, biological and surgical interventions for inflammatory bowel disease
por: Pillai, Nadia, et al.
Publicado: (2017)